• European Medicines Agency validates Immunome's marketing application for varegacestat to treat adults with desmoid tumors, initiating regulatory review.
• The FDA previously accepted the drug's application, setting a target decision date of April 28, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261030925417) on October 30, 2026, and is solely responsible for the information contained therein.